False Claims Act
RegulationWatch reporting on false claims act matters involving US pharmaceutical manufacturers, PBMs and healthcare companies, newest first.
- 340B Program (1)
- Anti-Kickback Statute (3)
- Antitrust (6)
- Controlled Substances Act (3)
- Drug Pricing (8)
- Drug Promotion (1)
- FTC Enforcement (2)
- FTC Report (1)
- False Claims Act (9)
- Marketing Fraud (2)
- Medicare Advantage (1)
- Medicare Negotiation (1)
- Merger Conditions (1)
- Off-Label Promotion (1)
- Opioid Distribution (1)
- Opioid Litigation (4)
- PBM Oversight (1)
- PBM Rebates (7)
- Patent Litigation (1)
- State Enforcement (4)
- False Claims Act
DOJ and HHS open six-month window for healthcare companies to self-disclose False Claims Act violations
A new pilot lets healthcare companies, including drug manufacturers, resolve previously unknown False Claims Act exposure by repaying 1.25 to 1.6 times the base amount. Participants avoid exclusion, corporate integrity agreements and civil monetary penalties.
- False Claims Act
A jury found 3.3 million false claims at CVS's Omnicare. The $948.8 million judgment is settling for $440 million.
Omnicare filed for bankruptcy two months after the judgment. The government now stands to collect less than half, and CVS admits nothing.
- False Claims Act
Dompé funded the charities that paid its own drug's copays. It cost $32 million.
The company reported itself and got credit for it. The admissions it signed show how the arrangement was built around the launch of Oxervate.
- False Claims Act
Remedi SeniorCare settles federal allegations over prescriptions billed without valid orders
The Justice Department announced that Remedi SeniorCare Holding Corporation agreed to pay more than $5.3 million to the United States over allegedly invalid prescription claims. The settlement is based on ability to pay and provides for installment payments without an admission of liability.
- False Claims Act
Abbott agrees to nearly $385 million infant formula settlement
The Justice Department announced a settlement with Abbott Laboratories over allegedly noncompliant infant formula and nutritional products purchased through government programs. Abbott denied the allegations and did not admit facts or liability.
- False Claims Act
Dompé US to pay $32 million over self-disclosed Oxervate co-pay kickbacks
Dompé U.S. Inc. has agreed to pay $32 million to resolve Department of Justice allegations that it used two patient assistance foundations to cover Medicare co-pays for its drug Oxervate between 2018 and 2021. The conduct was self-disclosed by its Italian parent, and the company admitted certain facts as part of the settlement.
- False Claims Act
Amgen pleaded guilty over Aranesp and paid $762 million. Then it kept paying.
The 2012 plea is a criminal conviction. Further settlements followed within months and continued for years.
- False Claims Act
CVS admitted over-dispensing insulin for a decade. The price was $37.76 million.
The admission is rare. The penalty, spread over ten years of conduct across the country's largest pharmacy chain, is small.
- False Claims Act
Pfizer pays $59.7 million over Biohaven kickbacks tied to migraine drug Nurtec
Pfizer agreed to pay $59,746,277 to resolve DOJ allegations that its subsidiary Biohaven, before the acquisition, paid kickbacks to health care providers to induce prescriptions of Nurtec ODT. The government alleged speaker honoraria and high-end meals violated the Anti-Kickback Statute between March 2020 and September 2022.
